In an interview with Targeted Oncology, Zangmeister Cancer Center Medical Oncologist Jorge A. Rios, MD, discusses recent advances in non-small cell lung cancer and the role targeted and immune checkpoint inhibitor therapy has played in this progress. Read the article.